RT Journal Article
SR Electronic
T1 Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.08.21252741
DO 10.1101/2021.03.08.21252741
A1 Ilies Benotmane
A1 Gabriela Gautier-Vargas
A1 Noelle Cognard
A1 Jerome Olagne
A1 Francoise Heibel
A1 Laura Braun-Parvez
A1 Jonas Martzloff
A1 Peggy Perrin
A1 Bruno Moulin
A1 Samira Fafi-Kremer
A1 Sophie Caillard
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.03.08.21252741.abstract
AB Data concerning the anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in kidney transplant recipients (KTRs) are currently lacking. Here, we sought to examine this issue by analyzing the serological response observed in 241 KTRs after a first vaccine injection. Our results indicate that KTRs have a weak anti-SARS-CoV-2 antibody response, ultimately resulting in a low seroconversion rate (26/241, 10.8%). This phenomenon likely stems from a high immunosuppression burden in this clinical population.Competing Interest StatementDr. Caillard reports personal fees and non-financial support from Novartis, non-financial support from Sanofi, non-financial support from Astellas, outside the submitted work.Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research protocol was approved by the institutional review board of Strasbourg University Hospitals under reference number CPP-EST DC-2013-1990All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the findings from this study are available from the corresponding author upon reasonable request.